What is Excalia?

Excalia is a new slimming pill that got a lot of press attention when clinical trials were first announced in 2006 by the pharmaceutical research company Orexigen Therapeutics. News reports claimed that it could help you drop up to two dress sizes and there was great excitement about it.

How does Excalia Work?

Like Orexigen Therapeutic’s other weight loss drug in trials (Mysimba), Excalia contained two medications already licensed for use, an anti-depressive called Bupropion and an anti-seizure medication, Zonisamide.

Together, the two medications seem to reduce appetite and encourage greater expenditure of energy. Buproprion, raises levels of the neurotransmitter dopamine in the brain and so reduces appetite and the two medications together promote sustained weight loss.

I heard a lot about this Excalia, but nothing for a while - what is going on?

Excalia's name was changed to Empatic in 2007. Please see our Empatic page for further information about this medication.

For a free weight loss consultation, please click on the icon to the right. Our consultations are entirely free and without obligation to make a purchase. We can prescribe Xenical or Reductil.

Free Online Assessment Quick and Without Obligation

Diet Pills News

  • Experimental Drug Presented to Endocrine Society

    A large number of studies, both in humans and in animals, have looked at the mechanisms required for white adipose tissue to work as brown adipose tissue. However, until recently we were not aware of any studies that had considered whether there were any treatments that could affect this process.…

    Read full article >
  • Are Fat Burners Any Good?

    People who are looking to lose weight quite often (and totally understandably) want to explore the easiest option for shedding excess weight and it is not just the obese and overweight who are attracted to the prospect of popping a pill and watching the pounds melt away; gym bunnies are also…

    Read full article >
  • Contrave Heart Study Recruits Sought

    Orexigen Therapeutics has set out to recruit the 10,000 participants that it requires for the cardiovascular risk study of Contrave, its lead weight loss drug candidate. We have written about Contrave before and you may remember that the license application for the combination of bupropion and…

    Read full article >
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more Close